scispace - formally typeset
R

Rosita Accardi

Researcher at International Agency for Research on Cancer

Publications -  64
Citations -  2893

Rosita Accardi is an academic researcher from International Agency for Research on Cancer. The author has contributed to research in topics: Carcinogenesis & Gene silencing. The author has an hindex of 26, co-authored 63 publications receiving 2535 citations. Previous affiliations of Rosita Accardi include German Cancer Research Center.

Papers
More filters
Journal ArticleDOI

TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.

TL;DR: A novel mechanism used by HPV16 to suppress the host immune response by deregulating the TLR9 transcript is revealed, providing evidence that abolishing innate responses may be a crucial step involved in the carcinogenic events mediated by HPVs.
Journal ArticleDOI

The biological properties of E6 and E7 oncoproteins from human papillomaviruses

TL;DR: Most of the findings on the biological properties and molecular mechanisms of the oncoproteins E6 and E7 from mucosal and cutaneous HPV types are reviewed.
Journal ArticleDOI

The role of TP53 in Cervical carcinogenesis

TL;DR: The ability to promote p53 degradation is an exclusive property of E6 from the high‐risk HPV types, and the low‐risk E6 proteins lack this activity, although they can bind p53.
Journal ArticleDOI

The E6 and E7 Proteins of the Cutaneous Human Papillomavirus Type 38 Display Transforming Properties

TL;DR: This study characterized the in vitro properties of E7 proteins of three cutaneous HPV types, 10, 20, and 38, and shows that HPV38 E7 is able to inactivate the tumor suppressor pRb and induces loss of G1/S transition control, a key event in carcinogenesis.
Journal ArticleDOI

Role of human papillomaviruses in carcinogenesis.

TL;DR: The demonstration that high-risk HPV types are the etiological agents of cervical cancer allowed the implementation in the clinical routine of novel screening strategies for cervical lesions, as well as the development of a very efficient prophylactic vaccine.